Setback for LHON Treatment in the US: IMP Supports Urgent Patient Need
Setback for LHON Treatment in the US: IMP Supports Urgent Patient Need International Mito Patients (IMP), the global federation representing patient […]
Homepage News
EMA grants positive CHMP opinion for KYGEVVI® for Treatment of TK2d
EMA grants positive CHMP opinion for Kygevvi® for Treatment of TK2d International Mito Patients (IMP) and the global mitochondrial disease community
Funding for the SynLeigh Project to Advance New Therapies for Leigh Syndrome
Funding for the SynLeigh Project to Advance New Therapies for Leigh Syndrome IMP, Mitocon and Cure Mito Welcome ERDERA Funding International
IMP Annual Meeting 30-31 May 2026, France
IMP Annual Meeting 30-31 May 2026, France IMP’s Annual Meeting will take place 30–31 May 2026 at Brit Hotel Acropole,
Patients at the Heart of Research: IMP’s Role in the SIMPATHIC Drug Repurposing Project
Patients at the Heart of Research: IMP’s Role in the SIMPATHIC Drug Repurposing Project The SIMPATHIC project continues to make
Amplifying Our Collective Voice: IMP at National and International Events
Amplifying Our Collective Voice: IMP at National and International Events As members of IMP, we are part of a global
International MELAS Consensus Meeting in Pisa: A Milestone for Patient Advocacy and Research
International MELAS Consensus Meeting in Pisa: A Milestone for Patient Advocacy and Research From 28 to 30 November this autumn,
Mitochondrial Awareness Week 2025: 1.5million reached!!
Mitochondrial Awareness Week 2025: 1.5million reached!! This September, our community united for World Mitochondrial Disease Week, a celebration of green lights,
First patient with rare muscle disease treated with own stem cells
First patient with rare muscle disease treated with own stem cells 9 November 2025 Maastricht UMC+ has, for the first
IMP Welcomes FDA Approval of First-Ever Treatment for TK2d
IMP Welcomes FDA Approval of First-Ever Treatment for TK2d International Mito Patient (IMP) is delighted to welcome yesterday’s approval by